CAJ | 학술논문

目的：评价重组人血管内皮抑素（恩度）联合顺铂腹腔注射治疗恶性腹腔积液的疗效与安全性。方法：76例经病理确诊的晚期恶性肿瘤合并腹腔积液患者，行腹腔穿刺引流后，随机分为两组。试验组：腹腔注射重组人血管内皮抑素60毫克，顺铂40毫克 D1,4,7，三次为1周期；对照组：单用顺铂40毫克腹腔注射 D1,4,7，其余同试验组。按照WHO胸腹水疗效评价标准和NCI-CTC AE 4.0标准分别评估疗效及毒副反应。结果：试验组和对照组的客观有效率分别是65.7%和41.4%,，差异有统计学意义( p<0.05)；疾病控制率分别是94.2%和58.5%，差异有统计学意义( p<0.05)。试验组与对照组相比生活质量有改善的趋势。不良反应主要是白细胞减少，血小板下降，心脏毒性，恶心呕吐，两组无统计学差异( p>0.05)。结论：重组人血管内皮抑素（恩度）联合顺铂腹腔注射治疗恶性腹腔积液疗效好，毒副反应小，值得临床推广。
목적：평개중조인혈관내피억소（은도）연합순박복강주사치료악성복강적액적료효여안전성。방법：76례경병리학진적만기악성종류합병복강적액환자，행복강천자인류후，수궤분위량조。시험조：복강주사중조인혈관내피억소60호극，순박40호극 D1,4,7，삼차위1주기；대조조：단용순박40호극복강주사 D1,4,7，기여동시험조。안조WHO흉복수료효평개표준화NCI-CTC AE 4.0표준분별평고료효급독부반응。결과：시험조화대조조적객관유효솔분별시65.7%화41.4%,，차이유통계학의의( p<0.05)；질병공제솔분별시94.2%화58.5%，차이유통계학의의( p<0.05)。시험조여대조조상비생활질량유개선적추세。불량반응주요시백세포감소，혈소판하강，심장독성，악심구토，량조무통계학차이( p>0.05)。결론：중조인혈관내피억소（은도）연합순박복강주사치료악성복강적액료효호，독부반응소，치득림상추엄。
OBJECTIVE:To observe the clinical efficacy of recombinant human endostain combined with cis-platinum in the treatment of patients with maliganant peritoneal effusion.METHODS:76 patinets with maliganant peritoneal effusion,who were diagnosed by pathology,were randomly divided into two groups after abdominocentesis.Trial group were treated with endostain 60mg and cis-platinum 40mg each time on d1,d4,d7;control group were treated with monotherapy of cis-platinum 40mg with the same procedure..The efficacy was evaluated according to WHO criteria and safety according to NCI CTC AE 4.0 version criteria..RESULTS The objective response rate was 65.7% for trial group and 41.4% for control group,the difference was stastical significance(p<0.05).The disease control rate was 94.2% for trial group and 58.5% for control group, the difference was stastical significance(p<0.05). Trial group showed a tendency to improve the quality of life compared to control group..Toxicities mainly included neutropenia、 thrombocytopenia 、Cardiac toxicity and nausea/vomiting,but the difference was not significant (p>0.05). CONCLUSION :Recombinant hunan endostatin combined with cis-platinum is an effective and safety therapy for malignant peritoneal effusion,with fewer toxic reaction,which is wothy of spreading in the clinic.